- Home
- CNF vs EPIX Comparison
CNF vs EPIX Comparison
Compare CNF & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- EPIX
- Stock Information
- Founded
- CNF 1999
- EPIX 2009
- Country
- CNF China
- EPIX Canada
- Employees
- CNF N/A
- EPIX N/A
- Industry
- CNF Finance: Consumer Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- EPIX Health Care
- Exchange
- CNF Nasdaq
- EPIX Nasdaq
- Market Cap
- CNF 89.2M
- EPIX 73.5M
- IPO Year
- CNF 2018
- EPIX N/A
- Fundamental
- Price
- CNF $0.90
- EPIX $1.64
- Analyst Decision
- CNF
- EPIX Hold
- Analyst Count
- CNF 0
- EPIX 3
- Target Price
- CNF N/A
- EPIX $2.00
- AVG Volume (30 Days)
- CNF 44.7K
- EPIX 286.3K
- Earning Date
- CNF 12-24-2024
- EPIX 02-11-2025
- Dividend Yield
- CNF N/A
- EPIX N/A
- EPS Growth
- CNF N/A
- EPIX N/A
- EPS
- CNF 0.24
- EPIX N/A
- Revenue
- CNF $109,788,152.00
- EPIX N/A
- Revenue This Year
- CNF N/A
- EPIX N/A
- Revenue Next Year
- CNF $13.09
- EPIX N/A
- P/E Ratio
- CNF $4.00
- EPIX N/A
- Revenue Growth
- CNF 12.99
- EPIX N/A
- 52 Week Low
- CNF $0.81
- EPIX $1.40
- 52 Week High
- CNF $2.84
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- CNF 41.33
- EPIX 24.91
- Support Level
- CNF $0.81
- EPIX $1.63
- Resistance Level
- CNF $1.04
- EPIX $1.74
- Average True Range (ATR)
- CNF 0.08
- EPIX 0.06
- MACD
- CNF 0.01
- EPIX 0.11
- Stochastic Oscillator
- CNF 34.07
- EPIX 6.67
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.